A new digital health product for postpartum depression was designed with prescribers in mind. So-called “prescription digital therapeutics” are available by prescription only. No medication comes with the product—its therapeutics are CBT and other therapy techniques. While the prescription ensures professional supervision, self-help tools arguably don’t need such close management. Entrepreneurs saw a market for prescribers, undoubtedly impressed by the success of “over-the-counter” digital products for behavioral health. The FDA sustains this niche market by reviewing its clinical studies and supporting a prescriber’s control over use. This prescription barrier constrains both marketing and use of the product—consumers have no direct access. Who should use these products? They are recommended for mild to moderate conditions. We know less severe problems often respond to therapy and derivative products like digital tools. So, why is product access restricted via prescriber controls? One might conclude prescribers control access for their own gain. Products designed with consumers in mind function differently. They prioritize broad access with unguided use and make clinical assessments available for urgent needs. Some consumers need prescribers, but not for managing the use of digital tools. Read this and related articles on my blog: https://lnkd.in/gNdeRHPs
Ed Jones, Ph.D.’s Post
More Relevant Posts
-
CEO at Pharmtrue | Community Pharmacist | Healthcare Innovator | Advancing Accessibility and Affordability in Healthcare
Empowering Health: Unveiling the Truth About Suboxone & Advancements in … Join Dr. Joaquin Acosta on this special leap year edition of "Know Your Pharmacist Live" as we delve into pressing healthcare issues and transformative solutions. Today's segments are power-packed with enlightening discussions: Pharmacist Frontline: Dive into the complexities of Suboxone in opioid addiction. Understand the challenges and breakthroughs in Suboxone and Narcan access. Tech Talk: Explore the fusion of technology and healthcare with a focus on innovative smartphone-based cognitive assessments and their impact on Alzheimer's research. Enlightenment Hour: Rare Disease Day special – raising awareness and driving change for those living with rare diseases. A journey into the heart of healthcare advocacy. Herbal Wellness Corner: Sponsored by High Horse Cannabis Co., we examine the latest research on Cannabidiol and Tetrahydrocannabivarin's effects on Type 2 Diabetes. C…
www.linkedin.com
-
New publication out in MSJ! There are many treatment options for #multiplesclerosis, although, unfortunately, none are curative. Together with Erasmus MC - MS Center ErasMS we investigated if using high efficacy (but also high cost) therapies earlier would be cost-effective. This is relevant as using more costly, but also more effective therapies earlier in the treatment pathway is often not considered due to cost considerations in many countries. We learn three things: One: Certain 'early use of highly effective' therapy treatment-sequences are equally cost-effective to 'step-up' treatment sequences, with larger health gains, but also bearing a risk of overspending. Biosimilars would reduce this risk and make the strategy much more favourable. Two: when comparing 504 possible escalation treatment sequences, cladribine was observed as by far most cost-effective second line option, although its use in the Netherlands is fairly limited. Third: Earlier use of alemtuzumab (which is not frequently prescribed due to very rare side effects and reduced tolerance of prescribing neurologists and patients to its (manageable) side-effect profile) is very cost-effective and yields large health gains. In practice, however, it is generally considered a last resort. Three lessons that deserve follow-up in clinical practice! with Ide Smets, Simone Huygens Beatrijs Wokke and Joost Smolders https://lnkd.in/eihQiMCP
Benefits of early highly effective versus escalation treatment strategies in relapsing multiple sclerosis estimated using a treatment-sequence model - Ide Smets, Matthijs Versteegh, Simone Huygens, Beatrijs Wokke, Joost Smolders, 2024
journals.sagepub.com
-
How do you save $2.4B per year and reduce patient suffering during the trail-and-error prescription process for mental health treatment? Research shows that only 1/3 of patients respond to treatment and experience remission as the efficacy of medication can be limited by a patient's genetic response to medication. In 2022, Dr. Kennedy at CAMH's Tanenbaum Centre for Pharmacogenetics announced the results of a first-in-Canada study that showed pharmacogenetic testing, understanding the way individual genetic profiles affect how people respond to different medications, was associated with an 89% increase in remission rates for people with treatment-resistant depression, compared to treatment as usual. The average health care savings following pharmacogenetic testing per depression patient is over $3,000. If half of the 1.6 million Canadians with depression could get testing, the savings could total $2.4B per year, in addition to reducing patient suffering during the trail-and-error prescription process.
-
-
Value creator improving patient lives through impactful health intervention and education
High quality patient-provider therapeutic connections are more than shared decision making and are associated with better outcomes for patients and care providers (Rathert et al, 2023). Skills and system interventions can improve therapeutic connections between providers and patients.
Better outcomes through patient – Provider therapeutic connections? An exploratory study of proposed mediating variables
sciencedirect.com
-
PHTI Launches Groundbreaking Initiative Digital Health Technologies on Hypertension and Mental Health The Peterson Health Technology Institute (PHTI) is expanding its examination of digital health technologies (DHTs) to include hypertension management and mental health support. PHTI aims to provide insights into the clinical efficacy and economic implications of digital health solutions and promote evidence-based assessments. PHTI aligns with the Institute for Clinical and Economic Review (ICER) to ensure rigorous evaluation, filling the data void in this rapidly evolving field. The expansion reflects a proactive approach to addressing critical healthcare needs and meeting the evolving needs of patients and healthcare systems. PHTI aims to empower stakeholders with transparent and unbiased evaluations to make informed decisions about adopting DHTs. With millions of people affected by hypertension and mental health disorders, rigorous evaluation is necessary to assess the clinical effectiveness and economic viability of digital health solutions. PHTI aims to set a gold standard for evaluating DHTs and foster a culture of evidence-based decision-making. The evaluation will focus on remote monitoring, self-management, and reducing clinic visits for hypertension management, as well as virtual therapy, medication management, coaching, and peer support for mental health. PHTI seeks to provide invaluable insights that shape the future of digital health. For more details please click the link! https://lnkd.in/gnJjEHxZ #marketaccess #reimbursement #pricing #hta #heor #healtheconomics #medicaldevices #pharmaceutical
PHTI Launches Groundbreaking Initiative Digital Health Technologies on Hypertension and Mental Health
-
New FREE resource! I've got my health equity hat on today... I'm excited to announce that a new resource has just been uploaded to the Cultural Competency resource library: "Healthy Aging". Developing culturally safe practice includes providing the best care for patients of all ages. People aged 65 years and older comprise a significant portion of the patients healthcare providers see every day. What preconceived ideas about older people do you have that might be unconsciously affecting the way you provide care? Culturally safe practitioners regularly take the time to self reflect. I hope you take some time out today and enjoy using this fun, yet thought-provoking, resource. For access, click the link in my bio and I'll email you with the details. Subscribers are the first to receive the heads-up whenever a new resource drops. ----- Kia ora. 👋 I’m Claire. I'm a passionate health equity advocate. I produce resources to assist healthcare professionals provide culturally safe care to their patients. I'm also a precision medicine specialist... I partner with healthcare providers to personalise medication management for patients based on their unique genetic makeup. If you are interested in learning more about how pharmacogenomic testing can benefit you and your patients, DM me or comment “YES” below and I’ll be in touch. #healthequity #eldercare #precisionmedicine #pharmacogenetics #pgx #pharmacogenomics #pharmacist
-
-
Multiple Sclerosis has wide ranging impacts on patients’ and caregivers’ lives resulting in a significant socioeconomic burden. In a new survey-based patient study, conducted on behalf of Merck KGaA, #CRALifeSciences Tim Wilsdon, Artes Haderi and Elaine Damato provide new evidence on the impact of earlier access to highly effective disease-modifying treatments with more convenient administration frequency on the economic and societal burden reduction. We document the impact on patient well-being, mental health, family life, employment, and the burden on caregivers, and discuss policies to recognize the value of treatments and support patient choice on treatment and care options. To read the full report, click here: https://crai.news/frs
Assessment of the impact of earlier access to disease-modifying treatments with more convenient administration frequency in reducing the socioeconomic burden for multiple sclerosis patients in Europe | Insights & Events | Charles River Associates
crai.com
-
Behavior is comparable to disease in driving distress, illness, and dysfunction in primary care patients. Behavioral clinicians have solutions, but few are employed in the setting. We need to rectify this and prioritize behavior change in primary care. Countless patients need behavioral interventions, and clinicians today are making an impact in brief (20-minute) visits. Dysfunctional behavior exacerbates chronic diseases like diabetes and depression. For example, patients often fail to take helpful medications for many reasons. Dysfunctional behavior ranges in complexity and magnitude, impacting physical and emotional health. Behavior merits attention as a unique clinical domain, not just for contributing to many disease processes. Traditional solutions are inadequate. More behavioral training will not help PCPs succeed, and models like Collaborative Care cannot scale to meet the need. If behavior is as fundamental as disease in determining health and illness, we must reconfigure primary care and make behavior specialists routinely available. Over time, behavioral clinicians will be viewed as co-leaders of primary care teams, not simply adjunctive staff. Their accountability for the ubiquitous domain of behavior makes them essential clinical partners to PCPs. Each domain’s importance is undiminished by the other. See more 200-word essays on my website: https://lnkd.in/gDwmGpQW
Behavior Rivals Disease in Its Damaging Impact on Health
edjonesphd.com
-
Check out the latest #DigitalHealth news updates! 📲🧠 Scroll through the slides below ⬇ or click here to read more ➡ https://lnkd.in/emTDy5J8 📢 CMS Introduces New Reimbursement Plan for Digital Health in CY2025 PFS Draft Rule 📢 Digital Health Funding Reaches $5.7B in Early 2024 Despite Uncertain Market Conditions, Rock Health Reports 📢 AI-Driven Regard Secures $61M to Find Missed Illnesses 📢 Pomelo Care Raises $46M in Series B Funding Round 📢 Cumulus Neuroscience to Participate in Bio-Hermes 2 Study Backed by Innovate UK Small Business Research Initiative (SBRI) Dementia Mission Funding 📢 Carle Health Partners with Nabla for AI-Driven Scribe Support 📢 Kaia Health's App for Back Pain Reduces Pain Intensity 📢 New York City EMTs Experiment with Mental Health Video Game Zengence 📢 FDA-Approved Digital Therapeutic Stanza Demonstrates Positive Results for Fibromyalgia in Phase III Trials, Reported in The Lancet #CMS #Regard #PomeloCare #CumulusNeuroscience #CarleHealth #Nabla #KaiaHealth #Zengence #DigitalHealth #Healthcare #MedTech #HealthTech #AI #Funding #Innovation #HealthCareNews #DigitalTherapeutics #MedicalResearch #HealthStartups #SeriesB #MentalHealth #Fibromyalgia #SBRI #Medicare #Medicaid
-
💫 Meridian Diagnostics’ F.A.S.T. Approach: Elevating Care in Long-Term Facilities & Addiction Treatment Centers At Meridian Diagnostics, we understand the critical needs of #healthcare providers and their patients especially when it comes to UTI, Wound, Onychomychosis, and Toxicology testing. That's why we're proud to present our groundbreaking F.A.S.T. diagnostic service, designed to enhance patient care and streamline healthcare processes. Here’s how: 🔍 F - Functional: - Patient Relevance: Our diagnostics are tailored to provide relevant insights, aiding in precise and personalized patient care strategies. - Office Efficiency: We streamline operations within your practice, reducing wait times and administrative burdens, so you can focus on what you do best - caring for patients. - Test Menu Options: With an expansive range of tests, we cover various patient needs, ensuring you have the right tools at the right time. 🎯 A - Accurate: - Test Methods: Employing state-of-the-art technology for results you can trust. - Results & Processes: With a rigorous quality control system, we guarantee the accuracy of every result, supporting your clinical decisions. 🔄 S - Seamless: - Integration: Easy integration with existing systems for a smooth workflow. - Collection & Support: Hassle-free sample collection complemented by our dedicated support team, ready to assist you every step of the way. ⏰ T - Timely: - 24-48 Hour Turnaround: Fast results mean timely interventions. Our efficient processing ensures you receive accurate results within 24-48 hours for all tests on our menu, helping you make quicker, informed decisions for your patients. 🌈 Why Healthcare Providers Choose Meridian Diagnostics: - Comprehensive Care: Enhance your patient care with diagnostics that matter. - Efficient Practices: Save time and resources, focusing on patient care rather than administrative tasks. - Confident Decision Making: Rely on accurate, timely information to guide your treatment plans. 💡 Transform Your Healthcare Delivery with F.A.S.T. Diagnostics by Meridian. Contact us today & we make healthcare better, together. #HealthcareInnovation #PatientCare #LongTermCare #DrugRehabilitation #BehavioralHealth #HealthTech #DiagnosticExcellence #EfficientHealthcare #MedicalDiagnostics #HealthcareProviders #DiagnosticTesting
-
